0.05Open0.05Pre Close0 Volume61 Open Interest2.50Strike Price0.00Turnover430.92%IV264.29%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1975Delta0.4150Gamma14.00Leverage Ratio-0.0051Theta0.0000Rho2.77Eff Leverage0.0004Vega
Karyopharm Therapeutics Stock Discussion
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet